This review proposes that K2's substantial adverse impact incidence is because of, a minimum of partly, to distinct JWH-018 metabolite action for the cannabinoid one receptor (CB1R), and implies that metabolites of most medications, although not the carboxy metabolite, keep in vitro As well as in vivo activity at CB1Rs. https://mam-220143085.bcbloggers.com/30539267/eam2201-no-further-a-mystery